BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 11413167)

  • 1. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
    Foster CJ; Prosser DM; Agans JM; Zhai Y; Smith MD; Lachowicz JE; Zhang FL; Gustafson E; Monsma FJ; Wiekowski MT; Abbondanzo SJ; Cook DN; Bayne ML; Lira SA; Chintala MS
    J Clin Invest; 2001 Jun; 107(12):1591-8. PubMed ID: 11413167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The P2 receptors in platelet function.
    Hechler B; Cattaneo M; Gachet C
    Semin Thromb Hemost; 2005 Apr; 31(2):150-61. PubMed ID: 15852218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y12 receptor in platelet activation.
    Kim S; Kunapuli SP
    Platelets; 2011; 22(1):56-60. PubMed ID: 21231822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis.
    Savi P; Herbert JM
    Semin Thromb Hemost; 2005 Apr; 31(2):174-83. PubMed ID: 15852221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADP receptors of platelets and their inhibition.
    Gachet C
    Thromb Haemost; 2001 Jul; 86(1):222-32. PubMed ID: 11487010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
    Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
    Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, characterization, and inhibition of the platelet ADP receptors.
    Gachet C
    Int J Hematol; 2001 Dec; 74(4):375-81. PubMed ID: 11794691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ADP receptors in platelet function.
    Murugappa S; Kunapuli SP
    Front Biosci; 2006 May; 11():1977-86. PubMed ID: 16368572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists.
    Zhan C; Yang J; Dong XC; Wang YL
    J Mol Graph Model; 2007 Jul; 26(1):20-31. PubMed ID: 17110146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that the purinergic receptor P2Y12 potentiates platelet shape change by a Rho kinase-dependent mechanism.
    Hardy AR; Hill DJ; Poole AW
    Platelets; 2005 Nov; 16(7):415-29. PubMed ID: 16236603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet activation by ADP: the role of ADP antagonists.
    Gachet C
    Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the platelet ADP receptor targeted by antithrombotic drugs.
    Hollopeter G; Jantzen HM; Vincent D; Li G; England L; Ramakrishnan V; Yang RB; Nurden P; Nurden A; Julius D; Conley PB
    Nature; 2001 Jan; 409(6817):202-7. PubMed ID: 11196645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
    Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
    J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
    Kim S; Foster C; Lecchi A; Quinton TM; Prosser DM; Jin J; Cattaneo M; Kunapuli SP
    Blood; 2002 May; 99(10):3629-36. PubMed ID: 11986217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADP receptors--targets for developing antithrombotic agents.
    Kunapuli SP; Ding Z; Dorsam RT; Kim S; Murugappan S; Quinton TM
    Curr Pharm Des; 2003; 9(28):2303-16. PubMed ID: 14529392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.